stockrowMedpace Holdings, Inc.
MEDP Healthcare Diagnostics & Research
Medpace Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 20.0% from fiscal 2024.
- Revenue
- +8.50%
- EPS
- +24.6%
- Free cash flow
- −16.6%
Quarter to September 2026, against a year earlier
Follow MEDP
Alert me
Medpace Holdings, Inc. (MEDP) P/S ratio
As of 5 November 2026, Medpace Holdings, Inc. (MEDP) trades at a P/S ratio of 6.2×. Over the past ten years it has ranged from 0.0× (September 2016) to 7.5× (December 2021); the current reading is higher than 87% of that period. That is above the Diagnostics & Research industry median of 4.2× and above the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 6.4× | 31.31% |
| FY2024 | 4.9× | (2.04%) |
| FY2023 | 5.0× | 7.75% |
| FY2022 | 4.6× | (32.37%) |
| FY2021 | 6.8× | 27.53% |
| FY2020 | 5.4× | 52.92% |
| FY2019 | 3.5× | 31.19% |
| FY2018 | 2.7× | (19.71%) |
| FY2017 | 3.3× | 9.40% |
| FY2016 | 3.0× | — |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 6.1× | 14.57% |
| Jun 2026 | 5.4× | 5.15% |
| Mar 2026 | 5.1× | (20.35%) |
| Dec 2025 | 6.4× | 4.39% |
| 40 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| ICLR ICON PLC compare | 1.9× |
| LH Labcorp Holdings Inc. compare | 2.0× |
| DGX Quest Diagnostics Incorporated compare | 2.4× |
| CRL Charles River Laboratories International, Inc. compare | 3.8× |
| QGEN QIAGEN N.V. compare | 5.0× |
| RVTY Revvity Inc. compare | 5.7× |
| MEDP Medpace Holdings, Inc. | 6.2× |
| ILMN Illumina, Inc. compare | 7.0× |
| GH Guardant Health, Inc. compare | 16.2× |
| Diagnostics & Research industry median | 4.2× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on MEDP
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement